Symetrify

Company Overview

Snapshot

Founded in February 2022 by Asher Castiel and Ami Eyal, Symetrify operates with 1–10 employees. The company has raised $1M across one funding round from two investors, with eHealth Ventures as a lead investor. Symetrify ceased operations in August 2026.

Business overview

Symetrify develops the L-PACT, a neuromechanical wearable training device designed for assessing, treating, and preventing spinal kinetic dysfunctions associated with chronic low back pain (CLBP). The L-PACT aims to address the functional-mechanical root cause of CLBP by balancing the lumbo-pelvic load distribution axis base, offering an automated training solution to halt degenerative processes. Utilizing data-driven AI algorithms, the technology provides predictive markers for low back motion imbalances, delivering personalized therapeutic effects for patients and enhancing treatment capacity for clinicians. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare, targeting the United States market with a B2B business model.

Company Intelligence Q&A

What is Symetrify's primary product?

Symetrify's primary product is the L-PACT, a neuromechanical wearable training device for assessing, treating, and preventing spinal kinetic dysfunctions related to chronic low back pain (CLBP).

When was Symetrify founded?

Symetrify was founded in February 2022.

Who are the founders of Symetrify?

The co-founders of Symetrify are Asher Castiel and Ami Eyal.

What is the current status of Symetrify?

Symetrify ceased to operate in August 2026, and is currently non-active.

Which markets does Symetrify target?

Symetrify targets the United States market with its L-PACT device.